| Publications by Biophoenix' Principals |
| Cancer Therapeutics - Markets and Therapies | |
|---|---|
 | |
| Publisher: | FT Pharmaceuticals |
| Year of publication: | 1998 |
| Type of publication: | Management report |
| Publisher's reference (if any): | CTH97 |
| Author(s): | Sreten Bogdanovic |
| Approximate page count: | 200 |
| Price when published: | £375 |
Remarks:
| |
Cancer Therapeutics
An FT Management Report
Sreten Bogdanovic, Biophoenix
(1997)
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION
1.1 Setting the scene
1.2 Cancer as a clinical problem
1.3 Scientific fundamentals
1.4 General features of cancer
1.5 Environmental causes of cancer
1.6 Tissues and organs
1.7 Types of tumour
1.8 How tumours begin
1.9 Features of malignant cells
1.10 Metastasis
1.11 Staging and grading
1.12 Epidemiology
1.13 Overview of ten common cancers
1.13.1 Lung cancer
1.13.2 Cancer of the stomach
1.13.3 Cancer of the breast
1.13.4 Colorectal cancer
1.13.5 Cervical cancer
1.13.6 Blood-related malignancies
1.13.7 Bladder cancer
1.13.8 Oesophageal cancer
1.13.9 Cancer of the prostate
1.13.10 Skin cancer
CHAPTER 2 DIAGNOSIS OF CANCER
2.1 Introduction
2.1.1 Screening
2.1.2 Tumour diagnosis and prognosis
2.1.3 Tumour monitoring
2.2 In vivo cancer diagnostics
2.2.1 Physical examination and endoscopy
2.2.2 Introduction to imaging
2.2.3 Ultrasound imaging
2.2.4 X-ray imaging
2.2.5 CT scanning
2.2.6 Nuclear imaging
2.2.7 Positron emission tomography
2.2.8 Magnetic resonance imaging
2.3 In vitro cancer testing
2.3.1 Histology
2.3.1.1 Traditional histology techniques
2.3.1.2 Immunohistochemistry
2.3.2 Cytology and flow cytometry
2.3.3 Immunoassays
2.3.4 DNA diagnostics
2.3.5 Clinical chemistry
CHAPTER 3 TREATMENT OF CANCER
3.1 Introduction
3.2 Surgery
3.3 Radiotherapy
3.4 Chemotherapy
3.5 Immunotherapy
3.6 Cancer-related clinical trials
3.6.1 Phase I trials
3.6.2 Phase II trials
3.6.3 Phase III trials
3.6.4 Adjuvant trials
CHAPTER 4 ADVANCES IN THE DELIVERY OF ANTICANCERS
4.1 Novel drug delivery systems
4.1.1 Introduction
4.1.2 Polymeric implants
4.1.3 Liposomal delivery vehicles
4.1.4 Other drug carriers
4.1.5 Delivery of therapeutic proteins
4.2 Delivery of anticancer drugs to the brain
4.2.1 Polymeric brain implants
4.3 Targeted Delivery of toxins
CHAPTER 5 CYTOTOXICS
5.1 Antimetabolites
5.1.1 Introduction
5.1.2 Adenosine deaminase inhibitors
5.1.3 Adenosylmethionine decarboxylase inhibitors
5.1.4 Dihydrofolate reductase inhibitors
5.1.5 Nucleotide analogues
5.1.6 Glycinamide ribonucleoside transformylase
inhibitors
5.1.7 Hypoxanthine phosphoribosyltransferase inhibitors
5.1.8 Inosine monophosphate dehydrogenase inhibitors
5.1.9 Ribonucleoside diphosphate reductase inhibitors
5.1.10 Thymidylate synthase inhibitors
5.2 Alkylating agents
5.2.1 Introduction
5.2.2 Methylmelamines
5.2.3 Nitrogen mustards
5.2.4 Nitrosoureas
5.2.5 Alkyl sulfonates
5.2.6 Triazenes
5.2.7 Platinum-containing agents
5.2.8 Miscellaneous alkylating agents
5.2.9 Intercalating agents
5.3 DNA topoisomerase inhibitors
5.4 Antibiotics
5.4.1 Introduction
5.4.2 Actinomycins
5.4.3 Anthracyclines
5.4.4 Bleomycins
5.4.5 Mitomycin-C
5.4.6 Miscellaneous
CHAPTER 6 HORMONES AND THEIR ANTAGONISTS
6.1 Introduction
6.2 Androgen antagonists
6.3 Aromatase inhibitors
6.4 Osteogenic agents
6.5 Cytochrome P450 inhibitors
6.6 Oestrogen antagonists
6.7 Progesterone antagonists/agonists
6.8 Estrone sulfatase inhibitors
6.9 Growth hormone releasing factor antagonists
6.10 Adrenal steroid synthesis inhibitors
6.11 LHRH agonists and antagonists
6.12 Lyase and reductase inhibitors
6.13 Neuropeptide agents
CHAPTER 7 CANCER IMMUNOTHERAPY
7.1 Non-specific cancer immunotherapy
7.1.1 Evidence for non-specific immune response to
cancer
7.1.2 Immunostimulants
7.1.3 Interferons
7.1.4 Interleukins
7.1.5 Growth and inhibitory factors
7.2 Specific cancer immunotherapy
7.2.1 Evidence for specific immune response to cancer
7.2.2 Cancer vaccines
7.2.3 Adjuvants
7.2.4 Monoclonal antibodies
7.2.5 Lymphocytes
CHAPTER 8 MISCELLANEOUS AGENTS
8.1 Signal transduction inhibitors
8.1.1 Introduction
8.1.2 Overview
8.2 Apoptosis inducers
8.3 Metalloprotease inhibitors
8.4 Angiogenesis inhibitors
8.5 Microtubule antagonists
8.6 Differentiation inducers
CHAPTER 9 ADJUNCT THERAPIES
9.1 Radio- and chemoprotectives
9.1.1 Introduction
9.1.2 Cytokines and cytokine agonists
9.1.3 Other protective mechanisms
9.2 Radio- and chemosensitisers
9.3 Anti-emetics
9.3.1 Introduction
9.3.2 5-HT3 receptor antagonists
9.3.3 Cannabinoids and other agents
CHAPTER 10 FUTURE TRENDS: GENE THERAPY AND ANTISENSE AGENTS
10.1 Gene therapy approaches to treatment of cancer
10.1.1 Gene therapy as an aid to conventional
chemotherapy
10.1.1.1 Herpes simplex thymidine kinase-mediated
therapy
10.1.1.2 Introduction of multidrug resistance genes
10.1.2 Transgenic immunotherapy of cancer
10.1.2.1 Cytokine immunotherapy
10.1.2.2 Immunotherapy based on tumour-associated
antigens
10.1.3 Modification of expression of tumour suppressor
genes and oncogenes
10.1.3.1 Replacement of defective tumour suppressor
genes
10.1.3.2 Suppression of oncogene expression
10.1.4 Additional approaches under investigation
10.2 Antisense agents
10.2.1 Introduction
10.2.2 Overview
CHAPTER 11 COMPANY PROFILES
11.1 Introduction
11.2 ALLERGAN LIGAND RETINOID THERAPEUTICS (ALRT) INC
11.3 ARONEX PHARMACEUTICALS INC
11.4 BRISTOL MYERS SQUIBB CO
11.5 CELL GENESYS INC
11.6 COULTER PHARMACEUTICALS INC
11.7 CYTOCLONAL PHARMACEUTICS INC
11.8 GENETIC THERAPY Inc
11.9 GLAXO WELLCOME PLC
11.10 HOECHST AG
11.11 HOFFMAN-LA-ROCHE
11.12 HYBRIDON INC
11.13 IMMUNE RESPONSE CORP
11.14 LIGAND PHARMACEUTICALS INC
11.15 MATRIX PHARMACEUTICAL INC
11.16 MAXIM PHARMACEUTICALS INC
11.17 MGI PHARMA INC
11.18 NOVARTIS PHARMA AG
11.19 NU TECH BIO MED INC
11.20 ONYX PHARMACEUTICALS INC
11.21 PHARMAGENICS INC
11.22 SCHERING AG
11.23 SCHERING PLOUGH CORP
11.24 SEQUUS PHARMACEUTICALS INC
11.25 SPARTA PHARMACEUTICALS INC
11.26 SMITHKLINE BEECHAM plc
11.27 SYSTEMIX Inc
11.28 U S BIOSCIENCE INC
11.29 YAMANOUCHI PHARMACEUTICAL Co Ltd
11.30 ZENECA
LIST OF TABLES
Table 4.1 Novel anticancer drug delivery systems
Table 4.2 Antibody- and oligonucleotide-linked toxins under
development
TABLE 5.1 Launched antimetabolites
TABLE 5.2 Antimetabolites under development
TABLE 5.3 Launched alkylating and other DNA-targeting agents
TABLE 5.4 Alkylating and other DNA-targeting agents under
development
TABLE 5.5 Launched anticancer antibiotics
TABLE 5.6 Anticancer antibiotics under development
TABLE 6.1 Launched hormones and hormone antagonists
TABLE 6.2 Hormones and hormone antagonists under development
TABLE 7.1 Launched immunotherapeutics
TABLE 7.2 Immunotherapeutics under development
Table 8.1 Miscellaneous anticancer agents
Table 9.1 Cytokines and cytokine agonists
Table 9.2 Miscellaneous radio- and chemoprotective agents
Table 9.3 Radio- and chemosensitisers
Table 9.4 5-HT3 receptor antagonist anti-emetics
Table 9.5 Cannabinoid and other anti-emetics
Table 10.1 Gene therapy as an aid to conventional
chemotherapy
Table 10.2 Transgenic immunotherapy of cancer
Table 10.3 Gene therapies targeting tumour suppressor genes
and oncogenes
Table 10.4 Novel approaches to gene therapy of cancer
| |
